When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry. Please send the good word—or the bad—from your shop to Darren ...

Management reaffirmed guidance for 2025 on an expense base of less than $450 million, "excluding all of the partnership inflows." For 2026, guidance was also reaffirmed at less than $390 million.

While investor enthusiasm often focuses on big tech, clinical-stage biotech Recursion Pharmaceuticals (NASDAQ: RXRX) is emerging as a distinctive player in the AI-driven drug discovery space. Founded ...

Recursion, Roche, and its Genentech subsidiary have unveiled the latest product of their nearly four-year artificial intelligence (AI) drug discovery collaboration, a whole-genome map of specialized ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...

I'm diving deep into the intersection of infrastructure and machine learning. I'm fascinated by exploring scalable architectures, MLOps, and the latest advancements in AI-driven systems ...

America is the global leader in health care innovation. We lead in medical research and in rapidly developing treatments for emerging health care priorities. That leadership isn’t free. But it isn’t ...

This repository contains a collection of 140+ Python programs covering a wide range of fundamental concepts and problem-solving techniques. It is designed to help beginners and intermediate learners ...